These results supported that IL-17 inhibitors and IL-23 inhibitors may not increase the risk of tuberculosis, hepatitis, and herpes zoster in psoriasis patients without known diagnoses or previous histories of these infections. This evidence concerns the gene IL17A and hepatitis A virus infection.